Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

被引：2
|
作者：
Harbeck, N. [1 ]
Vazquez, R. Villanueva [2 ]
Tripathy, D. [3 ]
Lu, Y. [4 ]
De Laurentiis, M. [5 ]
Kuemmel, S. [6 ]
Taylor, D. [7 ]
Bardia, A. [8 ]
Hurvitz, S. [9 ]
Chow, L. [10 ]
Im, S. [11 ]
Franke, F. [12 ]
Hughes, G. [13 ]
Miller, M. [13 ]
Kong, O. [13 ]
Chandiwana, D. [13 ]
Colleoni, M. [14 ]
机构：
[1] Univ Munich LMU, Dept OB & GYN, Breast Ctr, Munich, Germany
[2] Hosp St Joan Despi Moises Broggi, Inst Catala Oncol, Barcelona, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Ist Nazl Tumori Fdn G Pascale, Naples, Italy
[6] Kliniken Essen Mitte, Breast Unit, Essen, Germany
[7] CHU UCL Namur Site St Elisabeth, Namur, Belgium
[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[9] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[10] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China
[11] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[12] Hosp Caridade Ijui, CACON, Ijui, Brazil
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Ist Europeo Oncol, Div Med Senol, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/S0959-8049(18)30260-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1LBA
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [31] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
    De Laurentiis, Michelino
    Campone, Mario
    Alba Conejo, Emilio
    Tanner, Minna
    Egle, Daniel
    Papai, Zsuzsanna
    Prat Aparicio, Aleix
    Dent, Susan
    Warner, Ellen
    Ankrah, Nii
    Wu, Jiwen
    Zhou, Katie
    Borstnar, Simona
    BREAST, 2019, 48 : S46 - S47
  • [33] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
    Salvador, J.
    Ciruelos, E. M.
    Prat, A.
    Jimenez-Rodriguez, B.
    de la Cruz, L.
    Martinez, N.
    Villanueva Vazquez, R.
    de Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Gavila, J.
    Quiroga, V.
    Vicente, E.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos Sanchez de Ibarguen, B.
    Delgado, J. I.
    Bellet, M.
    Gimeno, A.
    Sanz, S.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
    Constantinidou, Anastasia
    Marcou, Yiola
    Simmons, Timothy
    Bernhisel, Ryan
    Hughes, Elisha
    Meek, Stephanie
    Kakouri, Eleni I.
    Georgiou, Georgios
    Zouvani, Ioanna
    Savvidou, Gabriella
    Kuhl, Vanessa
    Doedt, Jennifer
    Wagner, Susanne
    Gutin, Alexander
    Lanchbury, Jerry
    Kronenwett, Ralf
    Rakha, Emad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] CompLEEment-1: Phase 3b study of ribociclib plus letrozole for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
    De Laurentiis, M.
    Martin Jimenez, M.
    Ring, A.
    Cottu, P.
    Zhou, K.
    Wu, J.
    Zarate, J. P.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [40] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S.
    Petrakova, K.
    Bianchi, G. Valeria
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Ji, Y.
    Wang, C.
    Deore, U.
    Chakravartty, A.
    Zarate, J. P.
    Taran, T.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1015 - 1024
12345